Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease

Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease

Investigation of the effectiveness of extracorporeal shock wave therapy in the treatment of Peyronie's disease.

The study is designed as a single-center, prospective clinical trial. Participants will be selected from among patients who present to the clinic and are diagnosed with stable stage Peyronie's disease. All participants who meet the eligibility criteria and provide written consent will undergo a standard Extracorporeal Shockwave Therapy protocol. All participants will be evaluated before and after treatment using the International Erectile Function Index-5 and the Quality of Life Questionnaire short form. The results will be statistically analyzed and interpreted.

Inclusion Criteria:

• Male individuals aged 18-65 years.
• Having been diagnosed with Peyronie's Disease that has been stable (without increasing pain and curvature) for at least 6 months.
• Presence of palpable penile plaque.

Exclusion Criteria:

• Acute inflammatory stage (painful, progressive)
• Having previously undergone surgery, needle therapy (e.g., Xiaflex), or Extracorporeal Shockwave Therapy for peyronie's disease.
• Uncontrolled diabetes, severe coagulopathy, or receiving anticoagulant therapy.
• History of penile cancer.
• Severe erectile dysfunction.
• Patients who are considered unable to comply with the study protocol or who cannot attend follow-up visits.